News

Cybersecurity and Hardware Set to Thrive in 2025: CIO Insights

Cybersecurity and Hardware Set to Thrive in 2025: CIO Insights

Strong Demand for Cybersecurity and Hardware in 2025

Recent surveys from Jefferies and Morgan Stanley highlight an encouraging trend for technology spending, with a specific focus on cybersecurity and hardware for the upcoming year. As CIOs predict a surge in expenditures, these critical areas are set to play pivotal roles in organizational financing.

CIO Surveys Reveal Spending Projections

According to Jefferies' latest survey involving 40 Chief Information Officers (CIOs), the anticipated budget growth for cybersecurity in 2025 is notable, expected to climb 6.1% year-over-year. Though this projection shows a minor decline from the 6.5% growth experienced in 2024, cybersecurity continues to be a leading priority.

Cybersecurity Outpaces Other IT Sector Investments

Despite the slight drop, cybersecurity's growth outpaces that of software, which is projected to grow by only 4.5%, and overall IT budgets anticipated to increase by 3.8%. This suggests a concentrated investment in protective technologies as organizations prioritize data security in an increasingly digital world.

Cloud Spending Set for Significant Growth

In addition to cybersecurity, cloud services are forecasted to enjoy a substantial rise. CIOs predict spending will escalate from a growth rate of 9.6% in 2024 to an impressive 11.9% in 2025. The emphasis on security when selecting cloud vendors is critical and benefits key market players in the sector.

Impact on Major Players

This positive outlook is advantageous for established firms like CrowdStrike and Palo Alto Networks, which specialize in cybersecurity solutions. Notably, Palo Alto Networks stands out among respondents, with a remarkable increase in expected spending from 15% in June 2024 to 56% presently, showcasing its growing relevance.

Hardware Spending Optimism

Equally, Morgan Stanley’s fourth-quarter VAR Survey reveals an even more upbeat forecast for hardware spending, projecting a year-over-year increase of 5.1% for 2025, which is a significant improvement from the previous year’s 1.7%. This optimism is largely driven by improvements in storage, servers, and PC markets.

Sector-Specific Growth Trends

Among these categories, storage is anticipated to see a robust growth rate of 5.9%. This bullish outlook substantiates Morgan Stanley's positive position on enterprise hardware, prompting an upgrade of firms like Ingram Micro, with an increased price target reflecting expected positive performance.

Conclusion: A Bright Future Ahead

The findings from both Jefferies and Morgan Stanley emphasize strong growth trajectories in both cybersecurity and hardware sectors. This indicates a sustained demand that organizations are likely to leverage as they enhance their technology infrastructures. By investing in these critical areas, businesses position themselves favorably to navigate potential challenges ahead, ensuring robust operational resilience.

Frequently Asked Questions

What are the key findings from the recent CIO surveys?

The surveys suggest significant growth in cybersecurity and hardware spending for 2025, signaling strong demand in these vital sectors.

How much is cybersecurity spending expected to increase?

CIOs anticipate a 6.1% increase in cybersecurity budgets for 2025, despite a slight drop from last year's projections.

What is the expected growth for cloud services?

Cloud service spending is forecasted to rise from 9.6% in 2024 to 11.9% in 2025, driven by a focus on security.

Which companies are expected to benefit from the growth in cybersecurity?

Companies like CrowdStrike and Palo Alto Networks are expected to gain significantly from the rising expenditure in cybersecurity.

What is the forecast for hardware spending?

Hardware spending is projected to grow by 5.1% year-over-year in 2025, showing optimism particularly in storage and server solutions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 38

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 47

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 44

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 38

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 43

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 35

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into AppLovin Corporation's Alleged Fraud

Updated Category News Views 386

Investigation into AppLovin Corporation In recent news, a substantial class action lawsuit has emerged against AppLovin Corporation (NASDAQ: APP). This national law firm, known for advocating for investors, aims to hold the company accountable for alleged securities law violations. Understanding the Class Action Lawsuit This lawsuit pertains to any individuals or entities...

Continue Reading
Safe Harbor Financial Expands Support for Cannabis Operators

Updated Category News Views 33

Safe Harbor Financial Takes Bold Step in Cannabis Financing In a remarkable move, Safe Harbor Financial has successfully arranged a secured credit facility valued at $1.07 million. This milestone supports a cannabis operator, marking a significant step in bolstering financial services within the cannabis industry. With their expertise in facilitating innovative financial...

Continue Reading
Nidec Corporation Faces Securities Investigation: Key Insights

Updated Category News Views 224

Understanding Nidec Corporation's Current Challenges Nidec Corporation is undergoing scrutiny due to serious allegations in its business practices. This Japanese manufacturer, known for its electronic components, faces potential claims of issuing misleading information to its investors. Recent developments have raised questions about its transparency and accountability in...

Continue Reading
Understanding HCI Group's Short Interest Trends and Insights

Updated Category News Views 126

An Overview of HCI Group's Short Interest HCI Group's short interest has sparked interest among traders and investors alike, showing a recent increase of 7.38% from the previous report. This shift indicates that there are currently around 404 thousand shares sold short, comprising 4.95% of the company’s total tradable shares. Observing the trading volume, it has been...

Continue Reading
Fresenius Kabi Introduces New Epinephrine Injection for Patients

Updated Category News Views 151

Fresenius Kabi Launches Epinephrine Injection, USP Fresenius Kabi, a proud branch of the Fresenius organization, has taken a significant step in enhancing its pharmaceutical portfolio in the United States by making available Epinephrine Injection, USP. This launch positions Fresenius Kabi at the forefront as it becomes the first company to offer a generic 1mg/1mL vial of...

Continue Reading